Lifestyle intervention in postmenopausal women: winning the game against diabetes.
Lifestyle intervention in postmenopausal women: winning the game against diabetes.
复制标题
绝经后妇女的生活方式干预：赢得对抗糖尿病的比赛。
DOI：
10.1097/gme.0b013e318221bafe
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Wellons,Melissa
中科院分区：
文献类型：
--
作者：
Wellons,Melissa
正如《更年期》的读者所知，美国正面临着人口老龄化和肥胖症流行，以及与这两种疾病相关的慢性健康状况，如糖尿病。美国人口普查局估计，到2050年，美国将有一半的女性年龄在45岁或以上。1根据疾病控制和预防中心的预测，2 2000年出生的女孩，也就是我们2050年的50岁患者，如果她是白人，她一生中患糖尿病的风险为30%。如果她是少数族裔，她有大约50%的风险。因此，Kim等人在本月的《更年期》杂志上发表的关于更年期和糖尿病发展之间关系的研究是一篇关于紧迫话题的及时文章。Kim等人对已完成的糖尿病预防计划(DPP)试验的数据进行了子分析。4 DPP是一项由美国国立卫生研究院资助的27个中心的随机临床试验，旨在确定生活方式干预和/或二甲双胍是否可以预防糖尿病高危人群的发病。超过三分之二的民进党研究人群是女性，几乎一半来自少数民族群体。试验的结果是非常重要的。在大约3年的随访中，二甲双胍和生活方式干预都降低了新发糖尿病的发生率。此外，生活方式干预被证明比二甲双胍更好，这种优势是由生活方式干预在45岁以上参与者中的出色表现推动的。
As the readers of Menopause are well aware, the United States is facing both an aging population and an obesity epidemic and the chronic health conditions, such as diabetes, that are associated with both. The US Census Bureau estimates that, by 2050, half of the number of women in the United States will be 45 years or older. 1 Based on projections of the Centers for Disease Control and Prevention, 2 a girl born in 2000, that is, our 50-year-old patient in 2050, has a 30% lifetime risk of developing diabetes if she is white. She has an approximately 50% risk if she is a minority. Kim et al's 3 research published in this month's Menopause on the relationship between menopause and diabetes development is thus a timely article on a pressing topic.Kim et al 3 performed subanalyses of data from the completed Diabetes Prevention Program (DPP) trial. 4 The DPP was a 27-center randomized clinical trial funded by the National Institutes of Health to determine whether a lifestyle intervention and/or metformin could prevent the onset of diabetes in individuals at high risk for the disease. More than two thirds of the DPP study population were women, and almost half were from an ethnic minority group. The results of the trial were highly significant. Both metformin and lifestyle intervention reduced the rate of new onset diabetes during approximately 3 years of follow-up. In addition, lifestyle intervention proved better than metformin, and this superiority was driven by the lifestyle intervention's outstanding performance in participants older than age 45 years.